408 related articles for article (PubMed ID: 28440953)
1. Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study.
Ben-Ami E; Barysauskas CM; Solomon S; Tahlil K; Malley R; Hohos M; Polson K; Loucks M; Severgnini M; Patel T; Cunningham A; Rodig SJ; Hodi FS; Morgan JA; Merriam P; Wagner AJ; Shapiro GI; George S
Cancer; 2017 Sep; 123(17):3285-3290. PubMed ID: 28440953
[TBL] [Abstract][Full Text] [Related]
2. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open-label phase 2 trial.
Tamura K; Hasegawa K; Katsumata N; Matsumoto K; Mukai H; Takahashi S; Nomura H; Minami H
Cancer Sci; 2019 Sep; 110(9):2894-2904. PubMed ID: 31348579
[TBL] [Abstract][Full Text] [Related]
4. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
Rizvi NA; Mazières J; Planchard D; Stinchcombe TE; Dy GK; Antonia SJ; Horn L; Lena H; Minenza E; Mennecier B; Otterson GA; Campos LT; Gandara DR; Levy BP; Nair SG; Zalcman G; Wolf J; Souquet PJ; Baldini E; Cappuzzo F; Chouaid C; Dowlati A; Sanborn R; Lopez-Chavez A; Grohe C; Huber RM; Harbison CT; Baudelet C; Lestini BJ; Ramalingam SS
Lancet Oncol; 2015 Mar; 16(3):257-65. PubMed ID: 25704439
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors.
George S; Feng Y; Manola J; Nucci MR; Butrynski JE; Morgan JA; Ramaiya N; Quek R; Penson RT; Wagner AJ; Harmon D; Demetri GD; Krasner C
Cancer; 2014 Mar; 120(5):738-43. PubMed ID: 24222211
[TBL] [Abstract][Full Text] [Related]
6. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Hamanishi J; Mandai M; Ikeda T; Minami M; Kawaguchi A; Murayama T; Kanai M; Mori Y; Matsumoto S; Chikuma S; Matsumura N; Abiko K; Baba T; Yamaguchi K; Ueda A; Hosoe Y; Morita S; Yokode M; Shimizu A; Honjo T; Konishi I
J Clin Oncol; 2015 Dec; 33(34):4015-22. PubMed ID: 26351349
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients.
Mancari R; Signorelli M; Gadducci A; Carinelli S; De Ponti E; Sesana S; Corso S; Chiappa V; Colombo N; Lissoni AA
Gynecol Oncol; 2014 Jun; 133(3):531-6. PubMed ID: 24631454
[TBL] [Abstract][Full Text] [Related]
8. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
Min Lee CK; Li S; Tran DC; Zhu GA; Kim J; Kwong BY; Chang ALS
J Am Acad Dermatol; 2018 Dec; 79(6):1047-1052. PubMed ID: 29857011
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
10. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.
George S; Miao D; Demetri GD; Adeegbe D; Rodig SJ; Shukla S; Lipschitz M; Amin-Mansour A; Raut CP; Carter SL; Hammerman P; Freeman GJ; Wu CJ; Ott PA; Wong KK; Van Allen EM
Immunity; 2017 Feb; 46(2):197-204. PubMed ID: 28228279
[TBL] [Abstract][Full Text] [Related]
11. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
13. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.
Pautier P; Floquet A; Chevreau C; Penel N; Guillemet C; Delcambre C; Cupissol D; Selle F; Isambert N; Piperno-Neumann S; Thyss A; Bertucci F; Bompas E; Alexandre J; Collard O; Lavau-Denes S; Soulié P; Toulmonde M; Le Cesne A; Lacas B; Duffaud F;
Lancet Oncol; 2015 Apr; 16(4):457-64. PubMed ID: 25795402
[TBL] [Abstract][Full Text] [Related]
14. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.
Sznol M; Ferrucci PF; Hogg D; Atkins MB; Wolter P; Guidoboni M; Lebbé C; Kirkwood JM; Schachter J; Daniels GA; Hassel J; Cebon J; Gerritsen W; Atkinson V; Thomas L; McCaffrey J; Power D; Walker D; Bhore R; Jiang J; Hodi FS; Wolchok JD
J Clin Oncol; 2017 Dec; 35(34):3815-3822. PubMed ID: 28915085
[TBL] [Abstract][Full Text] [Related]
15. External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma.
Iasonos A; Keung EZ; Zivanovic O; Mancari R; Peiretti M; Nucci M; George S; Colombo N; Carinelli S; Hensley ML; Raut CP
Cancer; 2013 May; 119(10):1816-22. PubMed ID: 23456762
[TBL] [Abstract][Full Text] [Related]
16. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.
Carbognin L; Pilotto S; Milella M; Vaccaro V; Brunelli M; Caliò A; Cuppone F; Sperduti I; Giannarelli D; Chilosi M; Bronte V; Scarpa A; Bria E; Tortora G
PLoS One; 2015; 10(6):e0130142. PubMed ID: 26086854
[TBL] [Abstract][Full Text] [Related]
17. Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma.
Lamm W; Natter C; Schur S; Köstler WJ; Reinthaller A; Krainer M; Grimm C; Horvath R; Amann G; Funovics P; Brodowicz T; Polterauer S
BMC Cancer; 2014 Dec; 14():981. PubMed ID: 25523155
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Brahmer J; Reckamp KL; Baas P; Crinò L; Eberhardt WE; Poddubskaya E; Antonia S; Pluzanski A; Vokes EE; Holgado E; Waterhouse D; Ready N; Gainor J; Arén Frontera O; Havel L; Steins M; Garassino MC; Aerts JG; Domine M; Paz-Ares L; Reck M; Baudelet C; Harbison CT; Lestini B; Spigel DR
N Engl J Med; 2015 Jul; 373(2):123-35. PubMed ID: 26028407
[TBL] [Abstract][Full Text] [Related]
19. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.
Zimmer L; Apuri S; Eroglu Z; Kottschade LA; Forschner A; Gutzmer R; Schlaak M; Heinzerling L; Krackhardt AM; Loquai C; Markovic SN; Joseph RW; Markey K; Utikal JS; Weishaupt C; Goldinger SM; Sondak VK; Zager JS; Schadendorf D; Khushalani NI
Eur J Cancer; 2017 Apr; 75():47-55. PubMed ID: 28214657
[TBL] [Abstract][Full Text] [Related]
20. Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy.
Shafqat H; Gourdin T; Sion A
Semin Oncol; 2018 Jun; 45(3):156-163. PubMed ID: 30348532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]